Patient-reported outcomes in OlympiA: a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer - Ganz, Patricia A.; Bandos, Hanna; Španić, Tanja; Friedman, Sue; Müller, Volkmar; Kuemmel, Sherko; Delaloge, Suzette; Brain, Etienne; Toi, Masakazu; Yamauchi, Hideko; de Dueñas, Eduardo-M.; Armstrong, Anne; et al. (Journal of clinical oncology, 2024)
Gesehen am 09.12.2024